Mad Money with Jim Cramer - MAD CAP RECAP - The Official Mad Money Blog
RSS FEED
FEATURED SLIDESHOW
Who Is The Worst CEO?Mad Money needed new inductees for its
Wall of Shame, so we asked viewers for
nominations.
RECENT POSTS
- Mad Mail: Chesapeake Energy Is Hiring?
- Lightning Round: Royal Dutch Shell, Bank of America, RF Micro Devices and More
- Lightning Round OT: Harley-Davidson, Heartland Payment and More
- Cramer’s Christmas List
- Cramer: This Stock Offers ‘Plenty of Upside’
- Cramer Cuts Through Bears' Bull to Explain Tuesday's Market
- Cramer: Buy These 2 Dividend Plays
- Remorseful Regulator Leads Reform Fight
- Lightning Round: AT&T, Verizon, Novartis and More
- Lightning Round OT: Alcoa, Weight Watchers and More
MAD MONEY FEATURES
PODCASTSWatch the Lightning Round whenever and wherever you want.
OFFICIAL MAD MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
CRAMERS SOUNDBOARDAdmit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.
CHECK OUT OUR PHOTOSCheck out Cramer on set, back to school, behind the scenes and more.
SHOP FOR MAD MERCHANDISEBuy Cramer books, bobbleheads and other Mad Money merchandise.
RING TONESPick up the phone! It's Cramer! New Mad Money sounds for your cell phone.
TEXT MESSAGE ALERTMad Money's mobile. Get show highlights sent to your phone.
Text Size 
Web Editor, Mad Money
When it comes to biotech stocks, it’s all about the drugs.
Earnings may be the determining buy or sell factor in other sectors, but this group lives and dies according to the next cutting-edge treatment. One such catalyst approaches for Immunogen, and Cramer thinks the stock may be worth the risk.
Immunogen [IMGN
Loading...
()
], a once high-flying name during the market’s 2000-era heyday, looks ready to take off again. The company is working along side Roche/Genetech[DNA
Loading...
()
] on the breast-cancer drug T-DM1, and Phase II results are due Dec. 12. If the news is good, Cramer said, “Immunogen will be up gigantically.”
Of course, the stock will head lower if the study’s data proves disappointing, but T-DM1 shows real promise. Cramer called it “a better version of Herceptin,” the $4 billion drug from Genetech that’s become the standard of care for treating breast cancer. What’s better, though, is that T-DM1 could work in cases where Herceptin doesn’t, and the former could replace the latter entirely.
If T-DM1 makes it to market, Immunogen would collect royalties worth as much as $350 million, which is almost as much as the company’s $390 million market cap. That’s why Cramer said the stock “could be a fantastic speculation.” To get as much information about IMGN as possible before endorsing the stock, he invited CEO and President Daniel Junius to the show. Watch the video for the full interview.
Call Cramer: 1-800-743-CNBC
Questions for Cramer?
Questions, comments, suggestions for the Mad Money website?
Data is a real-time snapshot *Data is delayed at least 15 minutes